Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 2040361

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2040361

High-throughput Genomic Screening For Preventive Healthcare Market Size, Share & Trends Analysis Report By Test type, By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

High-throughput Genomic Screening For Preventive Healthcare Market Summary

The global high-throughput genomic screening for preventive healthcare market size was estimated at USD 846.05 million in 2025 and is projected to reach USD 2,169.74 million by 2033, growing at a CAGR of 12.6% from 2026 to 2033. The market growth is driven by the transition from reactive treatment to personalized prevention supported by preventive and precision medicine.

Advancements in high-throughput genomic technologies are further accelerating market expansion by enabling faster, scalable, and more accurate genetic analysis. For instance, in 2025, BGI Genomics and the Thalassemia International Federation highlighted that high-throughput sequencing improved the accuracy of carrier and at-risk couple identification in thalassemia prevention programs. This advancement strengthens the preventive healthcare paradigm by enabling scalable, precise genetic risk assessments, further accelerating the growth of the high-throughput genomic screening market for preventive healthcare.

Rising consumer awareness and demand for genomic insights are primary drivers of the global high-throughput genomic screening market for preventive healthcare. Individuals are increasingly seeking actionable genetic information to anticipate and mitigate health risks, and this demand is directly driving the adoption of genomic screening technologies such as multi-gene panels and next-generation sequencing. which enables comprehensive risk profiling before symptoms arise. For instance, in 2026, a recent study from 23andMe demonstrated the real-world impact of consumer genomic insights on preventive healthcare: 82% of participants had no prior clinical genetic testing and were unaware of their genetic health risks before using a direct-to-consumer test. After sharing results with healthcare providers, 86% received one or more medical recommendations, including earlier screenings, medications, or preventive surgeries, and 88% of these recommendations were followed. Such real-world adoption demonstrates that consumer-driven demand for genomic insights is not only shaping individual health decisions but also accelerating the overall expansion of the preventive genomic screening market.

The shift from reactive treatment to personalized prevention is driving growth of the high-throughput genomic screening market, as it emphasizes early detection and individualized healthcare. Genetic screening enables the identification of monogenic diseases, hereditary cancer risks such as BRCA1/2 and Lynch syndrome, and metabolic conditions before symptoms appear. Proactive testing, particularly between ages 40-50, targets a critical window when chronic diseases or early-stage cancers often begin to develop. Notably, approximately 50 % of high-risk individuals for hereditary cancers lack a clear family history, meaning traditional reactive approaches would miss them. Tests such as BRCA1/2, CHEK2, and Lynch syndrome panels support personalized surveillance strategies, including earlier mammograms, colonoscopies, or prophylactic interventions. Pharmacogenomic screening further enhances prevention by guiding drug selection and dosage. Providing actionable insights before disease onset, this shift toward precision-based care is directly driving demand for high-throughput genomic screening technologies. For instance, in 2025, international healthcare provider Bupa's My Genomic Health program in the UK and Spain identified high-risk variants in 4 % of participants and polygenic risk markers in 75 %, enabling early preventive care. This initiative demonstrates how the move from reactive treatment to personalized prevention delivers tailored risk insights, drives adoption of genomic screening, and expands the preventive healthcare market.

Global High-throughput Genomic Screening For Preventive Healthcare Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global high-throughput genomic screening for preventive healthcare market report based on test type, technology, application, end-use, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Carrier Screening
    • Expanded Carrier Screening (ECS)
    • Targeted Carrier Screening
  • Predictive / Presymptomatic Testing
  • Non-Invasive Prenatal Testing (NIPT)
  • Preimplantation Genetic Testing (PGT)
  • Newborn Screening
  • Pharmacogenomic Testing
  • Others
  • Outlook (Revenue, USD Million, 2021 - 2033)
  • Next-Generation Sequencing (NGS)
  • Microarray-based analysis
  • PCR (Polymerase Chain Reaction)
  • FISH (Fluorescence in situ hybridization)
  • CRISPR-based screening platforms
  • Others
  • Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Cardiovascular diseases
  • Reproductive health & fertility
  • Neurodegenerative disorders
  • Rare genetic diseases
  • Metabolic & chronic disease risk profiling
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Diagnostic Laboratories
  • Specialized Genomic Labs
  • Direct-to-Consumer (DTC) Companies
  • Research Institutes & Biopharma Companies
  • Genetic Counseling Centers
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
Show more
Product Code: GVR-4-68040-895-8

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Type
    • 1.2.2. Technology
    • 1.2.3. Application
    • 1.2.4. End use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type Test Outlook
    • 2.2.2. Technology Outlook
    • 2.2.3. Application Outlook
    • 2.2.4. End Use Outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. High-Throughput Genomic Screening for Preventive Healthcare Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Consumer Awareness and Demand for Genomic Insights
      • 3.2.1.2. Shift from Reactive Treatment to Personalized Prevention Through Preventive and Precision Medicine
      • 3.2.1.3. Advancements in High-Throughput Genomic Technologies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Advanced Genomic Testing
      • 3.2.2.2. Regulatory and Data Privacy Challenges
  • 3.3. High-Throughput Genomic Screening for Preventive Healthcare Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. High-Throughput Genomic Screening for Preventive Healthcare Market: Test Type Estimates & Trend Analysis

  • 4.1. Test Type Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global High-Throughput Genomic Screening for Preventive Healthcare Market by Test Type
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.5. Carrier Screening
    • 4.5.1. Carrier Screening Market, 2021 - 2033 (USD Million)
  • 4.6. Predictive / Presymptomatic Testing
    • 4.6.1. Predictive / Presymptomatic Testing Market, 2021 - 2033 (USD Million)
  • 4.7. Non-Invasive Prenatal Testing (NIPT)
    • 4.7.1. Non-Invasive Prenatal Testing (NIPT)Market, 2021 - 2033 (USD Million)
  • 4.8. Preimplantation Genetic Testing (PGT)
    • 4.8.1. Preimplantation Genetic Testing (PGT) Market, 2021 - 2033 (USD Million)
  • 4.9. Newborn Screening
    • 4.9.1. Newborn Screening Market, 2021 - 2033 (USD Million)
  • 4.10. Pharmacogenomic Testing
    • 4.10.1. Pharmacogenomic Testing Market, 2021 - 2033 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. High-Throughput Genomic Screening for Preventive Healthcare Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global High-Throughput Genomic Screening for Preventive Healthcare Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Next-Generation Sequencing (NGS)
    • 5.5.1. Next-Generation Sequencing (NGS) Market, 2021 - 2033 (USD Million)
  • 5.6. Microarray-based analysis
    • 5.6.1. Microarray-based analysis Market, 2021 - 2033 (USD Million)
  • 5.7. PCR (Polymerase Chain Reaction)
    • 5.7.1. PCR (Polymerase Chain Reaction) Market, 2021 - 2033 (USD Million)
  • 5.8. FISH (Fluorescence in situ hybridization)
    • 5.8.1. FISH (Fluorescence in situ hybridization) Market, 2021 - 2033 (USD Million)
  • 5.9. CRISPR-based screening platforms
    • 5.9.1. CRISPR-based screening platforms Market, 2021 - 2033 (USD Million)
  • 5.10. Others
    • 5.10.1. Other Application Market, 2021 - 2033 (USD Million)

Chapter 6. High-Throughput Genomic Screening for Preventive Healthcare Market: Application Estimates & Trend Analysis

  • 6.1. Technology Market Share, 2025 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global High-Throughput Genomic Screening for Preventive Healthcare Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Oncology
    • 6.5.1. Oncology Market, 2021 - 2033 (USD Million)
  • 6.6. Cardiovascular diseases
    • 6.6.1. Cardiovascular Diseases Market, 2021 - 2033 (USD Million)
  • 6.7. Reproductive Health & Fertility
    • 6.7.1. Reproductive Health & Fertility Market, 2021 - 2033 (USD Million)
  • 6.8. Neurodegenerative disorders
    • 6.8.1. Neurodegenerative Disorders Market, 2021 - 2033 (USD Million)
  • 6.9. Rare Genetic Diseases
    • 6.9.1. Rare Genetic Diseases Market, 2021 - 2033 (USD Million)
  • 6.10. Metabolic & chronic disease risk profiling
    • 6.10.1. Metabolic & Chronic Disease Risk Profiling Market, 2021 - 2033 (USD Million)
  • 6.11. Others
    • 6.11.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. High-Throughput Genomic Screening for Preventive Healthcare Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2025 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Global High-Throughput Genomic Screening for Preventive Healthcare Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.5. Hospitals & Diagnostic Laboratories
    • 7.5.1. Hospitals & Diagnostic Laboratories Market, 2021 - 2033 (USD Million)
  • 7.6. Specialized Genomic Labs
    • 7.6.1. Specialized Genomic Labs Market, 2021 - 2033 (USD Million)
  • 7.7. Direct-to-Consumer (DTC) Companies
    • 7.7.1. Direct-to-Consumer (DTC) Companies Market, 2021 - 2033 (USD Million)
  • 7.8. Research Institutes & Biopharma Companies
    • 7.8.1. Research Institutes & Biopharma Companies Market, 2021 - 2033 (USD Million)
  • 7.9. Genetic Counseling Centers
    • 7.9.1. Genetic Counseling Centers Market, 2021 - 2033 (USD Million)

Chapter 8. High-Throughput Genomic Screening for Preventive Healthcare Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2025
    • 9.3.4. Illumina, Inc
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Thermo Fisher Scientific Inc
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. BGI Genomics.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. 10x Genomics
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Pacific Biosciences
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Natera, Inc
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Myriad Genetics, Inc
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Fulgent Genetics
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Exact Sciences Corporation
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. 23andMe
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Color Health, Inc
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-895-8

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 4 Global high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 5 Global high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 6 Global high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 7 North America high-throughput genomic screening for preventive healthcare market, by Country, 2021 - 2033 (USD Million)
  • Table 8 North America high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 9 North America high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 10 North America high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 11 North America high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 12 U.S. high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 13 U.S. high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 14 U.S. high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 15 U.S. high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 16 Canada high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 17 Canada high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 18 Canada high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 19 Canada high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 20 Mexico high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 21 high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 22 Mexico high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 23 Canada high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 24 Europe high-throughput genomic screening for preventive healthcare market, by Country, 2021 - 2033 (USD Million)
  • Table 25 Europe high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 26 Europe high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 27 Europe high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 28 Europe high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 29 Germany high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 30 Germany high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 31 Germany high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 32 Germany high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 33 UK high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 34 U.K high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 35 UK high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 36 U.K high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 37 France high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 38 France high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 39 France high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 40 France high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 41 Italy high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 42 Italy high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 43 Italy high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 44 Italy high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 45 Spain high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 46 Spain high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 47 Spain high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 48 Spain high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 49 Denmark high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 50 Denmark high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 51 Denmark high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 52 Denmark high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 53 Sweden high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 54 Sweden high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 55 Sweden high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 56 Sweden high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 57 Norway high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 58 Norway high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 59 Norway high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 60 Norway high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific high-throughput genomic screening for preventive healthcare market, by Country, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 66 China high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 67 China high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 68 China high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 69 China high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 70 Japan high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 71 Japan high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 72 Japan high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 73 Japan high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 74 India high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 75 India high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 76 India high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 77 India high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 78 South Korea high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 79 South Korea high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 80 South Korea high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 81 South Korea high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 82 Australia high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 83 Australia high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 84 Australia high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 85 Australia high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 86 Thailand high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 87 Thailand high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 88 Thailand high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 89 Thailand high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 90 Latin America high-throughput genomic screening for preventive healthcare market, by Country, 2021 - 2033 (USD Million)
  • Table 91 Latin America high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 92 Latin America high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 93 Latin America high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 94 Latin America high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 95 Brazil high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 96 Brazil high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 97 Brazil high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 98 Brazil high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 99 Argentina high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 100 Argentina high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 101 Argentina high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 102 Argentina high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 103 Middle East & Africa high-throughput genomic screening for preventive healthcare market, by Country, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 108 South Africa high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 109 South Africa high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 110 South Africa high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 111 South Africa high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 112 Saudi Arabia high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 116 UAE high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 117 UAE high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 118 UAE high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 119 UAE high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)
  • Table 120 Kuwait high-throughput genomic screening for preventive healthcare market, by Test type, 2021 - 2033 (USD Million)
  • Table 121 Kuwait high-throughput genomic screening for preventive healthcare market, by Technology, 2021 - 2033 (USD Million)
  • Table 122 Kuwait high-throughput genomic screening for preventive healthcare market, by Application, 2021 - 2033 (USD Million)
  • Table 123 Kuwait high-throughput genomic screening for preventive healthcare market, by End use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 High-Throughput Genomic Screening for Preventive Healthcare Market Segmentation
  • Fig. 8 Market Snapshot, 2025
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Global high-throughput genomic screening for preventive healthcare market, Sample Movement Analysis
  • Fig. 16 Global High-Throughput Genomic Screening for Preventive Healthcare Market: Test type Movement Analysis
  • Fig. 17 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Predictive / Presymptomatic Testing, 2021 - 2033 (USD Million)
  • Fig. 18 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Non-Invasive Prenatal Testing (NIPT),2021 - 2033 (USD Million)
  • Fig. 19 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Preimplantation Genetic Testing (PGT),2021 - 2033 (USD Million)
  • Fig. 20 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Newborn Screening, 2021 - 2033 (USD Million)
  • Fig. 21 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Pharmacogenomic Testing,2021 - 2033 (USD Million)
  • Fig. 22 Global High-Throughput Genomic Screening for Preventive Healthcare Market, Technology Movement Analysis
  • Fig. 23 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Next-Generation Sequencing (NGS),2021 - 2033 (USD Million)
  • Fig. 24 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Microarray-based analysis,2021 - 2033 (USD Million)
  • Fig. 25 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for PCR (Polymerase Chain Reaction),2021 - 2033 (USD Million)
  • Fig. 26 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for FISH (Fluorescence in situ hybridization),2021 - 2033 (USD Million)
  • Fig. 27 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for CRISPR-based screening platforms 2021 - 2033 (USD Million)
  • Fig. 28 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Others 2021 - 2033 (USD Million)
  • Fig. 29 Global High-Throughput Genomic Screening for Preventive Healthcare Market, Application Movement Analysis
  • Fig. 30 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Oncology 2021 - 2033 (USD Million)
  • Fig. 31 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for cardiovascular diseases 2021 - 2033 (USD Million)
  • Fig. 32 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for reproductive health & fertility2021 - 2033 (USD Million)
  • Fig. 33 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for neurodegenerative disorders2021 - 2033 (USD Million)
  • Fig. 34 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for rare genetic diseases 2021 - 2033 (USD Million)
  • Fig. 35 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Metabolic & chronic disease risk profiling 2021 - 2033 (USD Million)
  • Fig. 36 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for others2021 - 2033 (USD Million)
  • Fig. 37 Global High-Throughput Genomic Screening for Preventive Healthcare Market, End Use Movement Analysis
  • Fig. 38 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Hospitals & Diagnostic Laboratories 2021 - 2033 (USD Million)
  • Fig. 39 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Specialized Genomic Labs 2021 - 2033 (USD Million)
  • Fig. 40 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Direct-to-Consumer (DTC) Companies 2021 - 2033 (USD Million)
  • Fig. 41 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Research Institutes & Biopharma Companies 2021 - 2033 (USD Million)
  • Fig. 42 Global High-Throughput Genomic Screening for Preventive Healthcare Market, for Genetic Counseling Centers 2021 - 2033 (USD Million)
  • Fig. 43 Regional Marketplace: Key Takeaways
  • Fig. 44 Regional Outlook, 2025 & 2033
  • Fig. 45 Global High-Throughput Genomic Screening for Preventive Healthcare Market, Region Movement Analysis
  • Fig. 46 North America high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 47 U.S. high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 48 Canada high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 49 Mexico high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 50 Europe high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 51 Germany high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 52 UK high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 53 France high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 54 Italy high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 55 Spain high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 56 Denmark high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 57 Sweden high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 58 Norway high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 59 Asia Pacific high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 60 Japan high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 61 China high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 62 India high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 63 Australia high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 64 South Korea high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 65 Thailand high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 66 Latin America high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 67 Brazil high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 68 Argentina high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 69 Middle East and Africa high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 70 South Africa high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 71 Saudi Arabia high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 72 UAE high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
  • Fig. 73 Kuwait high-throughput genomic screening for preventive healthcare market, 2021 - 2033 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!